{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:45:24Z","timestamp":1774359924310,"version":"3.50.1"},"reference-count":53,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.nephro.2011.03.002","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T01:36:44Z","timestamp":1330133804000},"page":"457-466","source":"Crossref","is-referenced-by-count":4,"title":["Actualit\u00e9s dans le traitement du my\u00e9lome avec insuffisance r\u00e9nale"],"prefix":"10.1684","volume":"7","author":[{"given":"\u00c9ric","family":"Moumas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hanf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Desport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Delb\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Debiais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Lacotte-Thierry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Touchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"issue":"9","key":"10.1016\/j.nephro.2011.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.nephro.2011.03.002_bib0010","first-page":"517","article-title":"Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975\u00a0and 1988","volume":"79","author":"Rayner","year":"1991","journal-title":"Q J Med"},{"key":"10.1016\/j.nephro.2011.03.002_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005792-198703000-00004","article-title":"Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34\u00a0patients","volume":"66","author":"Rota","year":"1987","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2011.03.002_bib0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0272-6386(87)80176-2","article-title":"Renal lesions in plasma cell dyscrasias: ultrastructural observations","volume":"10","author":"Pirani","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2011.03.002_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/JDI-100100888","article-title":"Renal involvement in multiple myeloma: a 10-year study","volume":"22","author":"Sakhuja","year":"2000","journal-title":"Ren Fail"},{"key":"10.1016\/j.nephro.2011.03.002_bib0030","doi-asserted-by":"crossref","first-page":"F82","DOI":"10.1152\/ajprenal.00091.2008","article-title":"Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000096762","article-title":"Proximal tubular injury in myeloma","volume":"153","author":"Batuman","year":"2007","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/ndt\/gfm670","article-title":"Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells","volume":"23","author":"Li","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2011.03.002_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0002-9343(84)90781-2","article-title":"Acute renal failure in patients with multiple myeloma","volume":"76","author":"Cohen","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2011.03.002_bib0050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1172\/JCI115629","article-title":"Pathobiology of cast nephropathy from human Bence Jones proteins","volume":"89","author":"Sanders","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2011.03.002_bib0055","unstructured":"Ronco PM, Aucouturier P, Mougenot B. Monoclonal gammopathies: multiple myeloma, amyloidosis, and related disorders. In: Schrier, Gottschalk. Dis Kidney 2001:2205\u201353."},{"key":"10.1016\/j.nephro.2011.03.002_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0065","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2011.03.002_bib0070","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.nephro.2011.03.002_bib0075","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94\u00a0patients from a single institution","volume":"158","author":"Blade","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.nephro.2011.03.002_bib0080","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0085","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2011.03.002_bib0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.2006080821","article-title":"Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies","volume":"18","author":"Hutchison","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0095","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0100","unstructured":"Bachmann U, Schindler R, Storr M, Kahl A, Joerres A, Sturm I. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. Nephrol Dial Transplant 2008. doi:10.1093\/ndtplus\/sfm 053."},{"key":"10.1016\/j.nephro.2011.03.002_bib0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5414\/CNP74319","article-title":"Prolonged hemodialysis for acute kidney injury in myeloma patients","volume":"74","author":"Hanf","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2011.03.002_bib0115","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2011.03.002_bib0120","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","article-title":"Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.nephro.2011.03.002_bib0125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3\u00a0study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.nephro.2011.03.002_bib0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05366.x","article-title":"Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure: a retrospective analysis and recommendations for dose adjustment","volume":"128","author":"Carlson","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2141.2001.03206.x","article-title":"British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma","volume":"115","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0140","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0145","first-page":"351","article-title":"The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients","volume":"82","author":"Celesti","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.nephro.2011.03.002_bib0150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0155","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.nephro.2011.03.002_bib0160","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0165","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1211\/0022357022241","article-title":"Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis","volume":"55","author":"Eriksson","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04395_2.x","article-title":"Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia","volume":"122","author":"Harris","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2004.04875.x","article-title":"Thalidomide in patients with multiple myeloma and renal failure","volume":"125","author":"Fakhouri","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0185","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0190","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2011.03.002_bib0195","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/10428190802023707","article-title":"Azotemia associated with use of lenalidomide in plasma cell dyscrasias","volume":"49","author":"Batts","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.nephro.2011.03.002_bib0200","doi-asserted-by":"crossref","unstructured":"Specter R, Sanchorawala V, Seldin DC, Shelton A, Fennessey S, Finn KT, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2010 [Epub ahead of print].","DOI":"10.1093\/ndt\/gfq482"},{"key":"10.1016\/j.nephro.2011.03.002_bib0205","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2011.03.002_bib0210","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/10428190801930506","article-title":"Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens","volume":"49","author":"Roussou","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.nephro.2011.03.002_bib0215","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","article-title":"Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.nephro.2011.03.002_bib0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0225","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0230","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","article-title":"Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents","volume":"34","author":"Roussou","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.nephro.2011.03.002_bib0235","first-page":"947","article-title":"Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study","volume":"2","author":"Tricot","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2011.03.002_bib0240","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"144","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0245","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","article-title":"Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure","volume":"75","author":"Knudsen","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.nephro.2011.03.002_bib0250","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","article-title":"Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.nephro.2011.03.002_bib0255","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.nephro.2011.03.002_bib0260","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.bmt.1704948","article-title":"Melphalan 200mg\/m2\u00a0with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival","volume":"35","author":"Carlson","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nephro.2011.03.002_bib0265","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","article-title":"Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant","volume":"33","author":"Lee","year":"2004","journal-title":"Bone Marrow Transplant"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725511000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725511000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2011.03.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:42:04Z","timestamp":1741182124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725511000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1769725511000526"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2011.03.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}